viewPressure BioSciences, Inc.

Pressure BioSciences sees record consumables sales in 2Q, momentum from launch of CBD processing system

CEO Richard Schumacher expects demand for the BaroShear K45 system to grow as it fixes a critical problem facing CBD manufacturers: the poor water solubility of CBD oil

Pressure BioSciences Inc. -
The CBD market is expected to hit $20 billion by 2024

Pressure BioSciences Inc (OTCMKTS:PBIO) said Thursday that its second quarter saw strong consumables sales and serious momentum from the launch of its water-soluble CBD manufacturing system.

In a statement accompanying the company’s latest numbers, Pressure BioSciences CEO Richard Schumacher said, “Due to the poor water solubility of today’s oil-based CBD products, most ingested CBD is flushed from the body, leaving little of the product to provide its beneficial properties.

“After much diligence and analysis, we concluded that we have the expertise and experience to successfully address this critical issue. Consequently, we pulled significant hours away from many of our staff over the past few months and had them focus on the development of an instrument system — based on our patented UST platform — that would increase the water solubility, and thus the absorption, of CBD Oil. We succeeded; the result of that success is the BaroShear K45 processing system.”

The current absorption rate for orally consumed CBD is typically below 10%, but the company said the BaroShear K45 system could deliver up to a 90% rate.

READ: Pressure BioSciences wins first customer for its water-soluble CBD manufacturing system

Schumacher said the company expects demand for the system to grow.

“The CBD market is expected to hit $20 billion by 2024. There are currently hundreds upon hundreds of companies in this field. To survive, companies will need to differentiate themselves from the competition by delivering the highest quality products possible. Such products would undoubtedly need to have high water-solubility, absorption, and bioavailability. This is exactly what we intend to deliver.”

Schumacher concluded: “We have already begun to pre-sell limited quantities of the BaroShear K45. Units sold over the coming weeks will be delivered and installed in early 2020. We believe that such sales will have a significant impact on 2020 total revenue, potentially resulting in more than twice the total revenue of 2019.”

For the quarter ended June 30, the Pressure Bio’s revenue declined 19% to $518,700, compared to $638,800 for the same period in the previous year. Sales of consumables shot up 43% to $91,400 in the second quarter, compared to $64,100 in the same period in the previous year.

“We believe that revenue from our BaroFold platform contract services will continue to increase, and that the decline in PCT platform instrument sales observed over the past two quarters caused in part by our focus on the development of the BaroShear K45 will end, and that we will see an increase in PCT product sales over the second half of 2019,” said Schumacher.

Pressure BioScience's shares closed at $2.25 on Thursday.

Contact Uttara Choudhury at [email protected]

Follow her on Twitter: @UttaraProactive

Quick facts: Pressure BioSciences, Inc.

Price: 2.25 USD

Market: OTCQB
Market Cap: $6.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Pressure BioSciences, Inc. named herein, including the promotion by the Company of Pressure BioSciences, Inc. in any Content on the Site, the...



Full interview: Pressure BioSciences PCT instrument deemed ‘essential’ by...

Pressure BioSciences Inc (OTCMKTS:PBIO) CEO Ric Schumacher tells Proactive the Massachusetts-based company’s patented pressure cycling technology (PCT) was featured in a presentation at the Annual Meeting of the Gynecologic Cancer Society in Brazil.  Schumacher explains the company’s PCT...

on 10/04/2019

3 min read